Does Longitudinal Nursing Follow-up Improve Smoking Cessation in Patients Referred for COPD Screening

NCT ID: NCT05577767

Last Updated: 2025-09-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

233 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-11

Study Completion Date

2026-09-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

a monocentric study to evaluate the efficacy of a longitudinal nursing follow up in smoking cessation in patients screened for Chronic obstructive pulmonary disease (COPD).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The challenges to limit the occurrence of COPD are early detection, the fight against smoking and smoking and addictions (e.g. Cannabis), as well as the fight against environmental exposures.

we proposed to evaluate if a longitudinal nursing follow-up at 3 months, 6 months and one year, in patients coming to screening for COPD.

Cessation of respiratory toxics is the most effective intervention in stopping the progression of COPD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Nurse's Role

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Smoking patients screened for COPD between 35 years old 65 years old
* Read, write and understand the French language
* Patient affiliated to a social security system
* Written and signed informed consent

Exclusion Criteria

* Patients with a diagnosis of respiratory diseases
* Patients receiving inhaled respiratory therapy
* Persons unable to perform spirometry
* Pregnant women
* Refusal to participate in research
* Patient under guardianship, deprived of liberty, safeguard of justice
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier de Valence

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gilles RIVAL, MD

Role: PRINCIPAL_INVESTIGATOR

CH VALENCE

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ch Valence

Valence, Drome, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RIPH-CHV-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.